ALX Oncology旗下药物Evorpacept与Zanidatamab的联合治疗方案，在治疗晚期HER2阳性且CD47高表达乳腺癌患者的临床研究中取得突破性进展。最新数据显示，该疗法不仅能诱发显著的治疗反应，更展现出令人鼓舞的持久疗效。
这项临床研究聚焦于肿瘤治疗领域两大关键生物标志物——HER2与CD47的协同作用机制。Evorpacept作为CD47靶向药物，与靶向HER2的Zanidatamab形成治疗合力，通过双重作用路径抑制肿瘤生长。值得注意的是，在CD47高表达的患者亚群中，联合疗法呈现出尤为突出的应答持续性和疾病控制效果。
研究人员指出，该组合疗法为传统HER2靶向治疗耐药的患者提供了新的治疗方向。其作用机制可能通过调节肿瘤微环境中的免疫应答，增强抗体依赖性细胞毒性作用，从而突破现有治疗瓶颈。目前，该研究仍在持续推进中，后续数据将进一步揭示联合疗法的长期疗效与安全性特征。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.